ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review.Frontiers in pharmacology · 2025Pooled it
- An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side.Frontiers in neuroscience · 2021Pooled it
- Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol.Frontiers in behavioral neuroscience · 2020Pooled it
- The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.Physiology & behavior · 2019Pooled it
- Effects of dulaglutide on alcohol consumption during smoking cessation.JCI insight · 2023Trial
- Liraglutide restores impaired associative learning in individuals with obesity.Nature metabolism · 2023Trial
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.Drug and alcohol dependence · 2021Trial
- Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.Behavioural pharmacology · 2026Article
- Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.Obesity pillars · 2026Article
- GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation.Obesity (Silver Spring, Md.) · 2026Observational
- Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.Fundamental & clinical pharmacology · 2026Review
- Volitional cocaine taking engages distinct medium spiny neuron and astrocyte transcriptional programs in the rat nucleus accumbens.bioRxiv : the preprint server for biology · 2026Article
- A rapid review of the effects of GLP-1 receptor agonists on opioid and stimulant use-related outcomes.Drug and alcohol dependence reports · 2026Review
- Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats.bioRxiv : the preprint server for biology · 2026Article
- Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.BMJ open · 2026Article
- Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.Journal of clinical medicine · 2026Review
- GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory.Comprehensive physiology · 2026Review
- Brain Amylin Signaling, Feeding, and Reward.Comprehensive Physiology · 2026Review
- Tirzepatide attenuates mesolimbic cocaine-evoked dopamine levels and reduces cocaine taking, motivation and seeking behaviours in male rodents.EBioMedicine · 2026Article
- Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.Psychopharmacology · 2026Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Novel molecular targets are needed to develop new medications for the treatment of cocaine addiction. Here we investigated a role for glucagon-like peptide-1 (GLP-1) receptors in the reinstatement of cocaine-seeking behavior, an animal model of relapse. We showed that peripheral administration of the GLP-1 receptor agonist exendin-4 dose dependently reduced cocaine seeking in rats at doses that did not affect ad libitum food intake, meal patterns or body weight. We also demonstrated that systemic exendin-4 penetrated the brain where it putatively bound receptors on both neurons and astrocytes in the ventral tegmental area (VTA). The effects of systemic exendin-4 on cocaine reinstatement were attenuated in rats pretreated with intra-VTA infusions of the GLP-1 receptor antagonist exendin-(9-39), indicating that the suppressive effects of systemic exendin-4 on cocaine seeking were due, in part, to activation of GLP-1 receptors in the VTA. Consistent with these effects, infusions of exendin-4 directly into the VTA reduced cocaine seeking. Finally, extinction following cocaine self-administration was associated with decreased preproglucagon mRNA expression in the caudal brainstem. Thus, our study demonstrated a novel role for GLP-1 receptors in the reinstatement of cocaine-seeking behavior and identified behaviorally relevant doses of a GLP-1 receptor agonist that selectively reduced cocaine seeking and did not produce adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.